Alcon receives approval for acquisition of Sirion products
This article was originally published in Scrip
Executive Summary
Alcon has received regulatory approval in the US for the acquisition of the global rights to Sirion Therapeutics' Durezol (difluprednate ophthalmic emulsion 0.05%) and the full rights excluding Latin America to Zyclorin (cyclosporine).